ReviewNature reviews. Nephrology2012
Childhood nephrotic syndrome--current and future therapies.
Review in Nature reviews. Nephrology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.
- Corticosteroid therapy for nephrotic syndrome in children.The Cochrane database of systematic reviews · 2015Pooled it
- Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2013Trial
- Epigenetic mechanisms and steroid-resistant nephrotic syndrome: The future potential for SRNS diagnosis.iScience · 2026Review
- Hyperlipidemia in membranous nephropathy.Clinical kidney journal · 2026Review
- Risk factors for relapse of pediatric PNS based on oral health problems: a prediction model.BMC oral health · 2025Article
- Effects of tacrolimus on proteinuria in Chinese and Indian patients with idiopathic membranous nephropathy: the results of machine learning study.International urology and nephrology · 2024Article
- Glucocorticoid- and pioglitazone-induced proteinuria reduction in experimental NS both correlate with glomerular ECM modulation.iScience · 2024Article
- Enzyme-activatable kidney-targeted dendrimer-drug conjugate for efficient childhood nephrotic syndrome therapy.Theranostics · 2024Article
- CXCR2 Activated JAK3/STAT3 Signaling Pathway Exacerbating Hepatotoxicity Associated with Tacrolimus.Drug design, development and therapy · 2024Article
- Metabolomics Profiling of Nephrotic Syndrome towards Biomarker Discovery.International journal of molecular sciences · 2022Article
- The immunopathogenesis of idiopathic nephrotic syndrome: a narrative review of the literature.European journal of pediatrics · 2022Review
- Alteration of N6-methyladenosine epitranscriptome profile in lipopolysaccharide-induced mouse mesangial cells.Naunyn-Schmiedeberg's archives of pharmacology · 2022Article
- Case Report: The Application of Dupilumab in Atopic Dermatitis Children Complicated With Nephrotic Syndrome.Frontiers in medicine · 2022Article
- Exploring the mechanism of Jianpi Qushi Huayu Formula in the treatment of chronic glomerulonephritis based on network pharmacology.Naunyn-Schmiedeberg's archives of pharmacology · 2021Article
- The role of the immune system in idiopathic nephrotic syndrome.Molecular and cellular pediatrics · 2021Review
- The potential mechanism ofTranslational pediatrics · 2021Article
- All-case Japanese post-marketing surveillance of the real-world safety and efficacy of rituximab treatment in patients with refractory nephrotic syndrome.Clinical and experimental nephrology · 2021Article
- Article
- Serum and urine ANGPTL8 expression levels are associated with hyperlipidemia and proteinuria in primary nephrotic syndrome.BMC nephrology · 2021Article
- Sulfatase 2 Is Associated with Steroid Resistance in Childhood Nephrotic Syndrome.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of corticosteroids more than 50 years ago dramatically improved the prognosis of children with nephrotic syndrome. Corticosteroids remain the standard initial treatment for children with this disease, but a considerable proportion of patients do not respond and are therefore at risk of progressing to end-stage renal disease. Because of this risk, new therapeutic strategies are needed for steroid-resistant nephrotic syndrome. These strategies have historically focused on identifying effective alternative immunosuppressive agents, such as ciclosporin and tacrolimus, yet evidence now indicates that nephrotic syndrome results from podocyte dysfunction. Even conventional immunosuppressive agents, such as glucocorticoids and ciclosporin, directly affect podocyte structure and function, challenging the 'immune theory' of the pathogenesis of childhood nephrotic syndrome in which disease is caused by T cells. This Review summarizes the currently available treatments for childhood nephrotic syndrome, and discusses selected novel pathways in podocytes that could be targeted for the development of next-generation treatments for children with this syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.